Financials Novogene Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 30/04/2024 am IST			5-day change	1st Jan Change
14.3 ^CNY	+1.20%		+5.38%	-38.73%

12/04	Novogene Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
27/02	Novogene Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Capitalization ¹	16,528	10,561	9,714	5,906	-	-
Enterprise Value (EV) ¹	16,528	10,561	9,714	5,906	5,906	5,906
P/E ratio	71.2 x	60 x	53 x	28 x	22.8 x	18.9 x
Yield	-	0.18%	0.2%	0.7%	1.26%	-
Capitalization / Revenue	8.86 x	5.48 x	4.85 x	2.53 x	2.12 x	1.81 x
EV / Revenue	8.86 x	5.48 x	4.85 x	2.53 x	2.12 x	1.81 x
EV / EBITDA	42 x	32 x	27.9 x	15.3 x	12.9 x	11.2 x
EV / FCF	8,96,29,861 x	-	4,45,95,338 x	-	-	-
FCF Yield	0%	-	0%	-	-	-
Price to Book	9.22 x	5.37 x	3.96 x	2.25 x	2.06 x	1.86 x
Nbr of stocks (in thousands)	4,00,200	4,00,200	4,16,200	4,12,975	-	-
Reference price ²	41.30	26.39	23.34	14.30	14.30	14.30
Announcement Date	24/02/22	27/02/23	27/02/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1,490	1,866	1,926	2,002	2,334	2,782	3,265
EBITDA ¹	-	393.6	330	347.6	384.9	456.4	525.9
EBIT ¹	-	246.5	212.5	214.1	257	314.5	377.6
Operating Margin	-	13.21%	11.03%	10.69%	11.01%	11.31%	11.57%
Earnings before Tax (EBT) ¹	-	246.5	208.6	211.8	255	311.7	375.5
Net income ¹	-	225	177.2	177.4	213.3	260.8	314.3
Net margin	-	12.05%	9.2%	8.86%	9.14%	9.38%	9.62%
EPS ²	0.1000	0.5800	0.4400	0.4400	0.5100	0.6267	0.7550
Free Cash Flow	-	184.4	-	217.8	-	-	-
FCF margin	-	9.88%	-	10.88%	-	-	-
FCF Conversion (EBITDA)	-	46.85%	-	62.66%	-	-	-
FCF Conversion (Net income)	-	81.96%	-	122.77%	-	-	-
Dividend per Share ²	-	-	0.0470	0.0470	0.1000	0.1800	-
Announcement Date	22/03/21	24/02/22	27/02/23	27/02/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	-	184	-	218	-	-	-
ROE (net income / shareholders' equity)	-	14.7%	9.43%	8.48%	8.17%	9.19%	9.84%
ROA (Net income/ Total Assets)	-	9.11%	6%	5.35%	5.5%	5.95%	6%
Assets ¹	-	2,470	2,954	3,315	3,878	4,384	5,238
Book Value Per Share ²	-	4.480	4.910	5.890	6.350	6.930	7.680
Cash Flow per Share ²	-	0.7300	0.7600	0.8000	1.000	1.160	1.240
Capex ¹	-	109	217	116	161	168	171
Capex / Sales	-	5.84%	11.28%	5.81%	6.91%	6.02%	5.24%
Announcement Date	22/03/21	24/02/22	27/02/23	27/02/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.3 CNY

Average target price

21.48 CNY

Spread / Average Target

+50.23%

	1st Jan change	Capi.
NOVOGENE CO., LTD.	-38.73%	816M
SONIC HEALTHCARE LIMITED	-18.58%	8.3B
RADNET, INC.	+47.25%	3.78B
SYNLAB AG	-8.58%	2.47B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-38.71%	2.46B
DR. LAL PATHLABS LIMITED	-10.06%	2.31B
NEOGENOMICS, INC.	-5.44%	1.95B
FLEURY S.A.	-17.79%	1.59B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.78%	1.21B
METROPOLIS HEALTHCARE LIMITED	+6.69%	1.1B